
Sign up to save your podcasts
Or


In this week's podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Cerebral Embolic Protection After TAVI
- Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
- Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
- Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
II Renal Denervation
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
- A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
III Percutaneous Left Atrial Appendage Occlusion (LAAO)
- Amulet, Watchman 2.5 LAAO Outcomes Neck and Neck at 3 Years https://www.medscape.com/viewarticle/981199
- Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
IV Deprescribing Aspirin
- Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding https://www.medscape.com/viewarticle/981243
- Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796492
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
By Medscape4.9
862862 ratings
In this week's podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Cerebral Embolic Protection After TAVI
- Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
- Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
- Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
II Renal Denervation
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
- A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
III Percutaneous Left Atrial Appendage Occlusion (LAAO)
- Amulet, Watchman 2.5 LAAO Outcomes Neck and Neck at 3 Years https://www.medscape.com/viewarticle/981199
- Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
IV Deprescribing Aspirin
- Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding https://www.medscape.com/viewarticle/981243
- Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796492
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]

1,874 Listeners

327 Listeners

543 Listeners

706 Listeners

500 Listeners

167 Listeners

15 Listeners

16 Listeners

3,376 Listeners

137 Listeners

1,147 Listeners

62 Listeners

515 Listeners

362 Listeners

61 Listeners

26 Listeners

8 Listeners

265 Listeners

439 Listeners

271 Listeners